The North America PEGylated Proteins Market would witness market growth of 10.6% CAGR during the forecast period (2022-2028).
Out of a projected 29.5 million new cases of the disease each year, 16.4 million individuals are anticipated to pass away from cancer-related causes by 2040. In addition, as per the fact sheet from the Joint United Nations Program on HIV/AIDS estimates that 37.7 million persons were HIV-positive globally in 2020. (UNAIDS).
As a result, the burden of infectious and chronic diseases worldwide is expected to increase, increasing the demand for generating medicines. The expansion of the sector will be accelerated, and research will be encouraged. It is expected that COVID-19 will have a beneficial impact on the sector. In SARS-CoV-2 ICU patients, PEGylated Nanoparticle Albumin-Bound (PNAB)-steroidal.
Ginsenoside can successfully lower plasma levels of histone H4 and NETosis-Related Factors and reduce SREBP2-Mediated Systemic Inflammation, according to a study titled "PEGylated Nanoparticle Albumin-Bound Steroidogenic Ginsenoside. Derivatives Alleviate SARS PNAB-steroidal ginsenoside medications may be used to treat severe SARS-CoV-2 patients' common coagulation and cytokine storm symptoms. Given the extensive research operations using PEGylation technology, the COVID-19 pandemic had a positive effect on the industry.
In Canada and the USA, cancer is the second-leading cause of mortality, behind heart disease. In Northern America, it was anticipated that there would be 1.9 million new cancer diagnoses and 693,000 cancer deaths in 2018. While lung cancer continues to be the most prevalent cause of cancer death in both sexes, prostate and breast cancer are the most often diagnosed cancers in men and women, respectively.
The US market dominated the North America PEGylated Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $533.2 million by 2028.The Canada market is exhibiting a CAGR of 13.1% during (2022 - 2028). Additionally, The Mexico market would showcase a CAGR of 12.1% during (2022 - 2028).
Based on Product & Services, the market is segmented into Consumables and Services. Based on Type, the market is segmented into Colony-stimulating Factor, Interferons, Recombinant Factor VII, Erythropoietin and Others. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutes. Based on Application, the market is segmented into Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global PEGylated Proteins Market is Estimated to reach $2.1 Billion by 2028, at a CAGR of 11.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck Millipore (Merck KGaA), Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology Co. Ltd., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd., Biomatrik, Inc., Iris Biotech GmbH, and Laysan Bio, Inc.
By Product & Services
By Type
By End-user
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
